Ulinastatin Reduces Cancer Recurrence after Resection of Hepatic Metastases from Colon Cancer by Inhibiting MMP-9 Activation via the Antifibrinolytic Pathway

<table>Gelatin zymography detects the effect of ulinastatin on MMP-9 activity. Horizontal ordinate: (1) control group without reagents; (2) low-dose ulinastatin (L-UTI) group, 800 U/mL ulinastatin; (3) high-dose ulinastatin (H-UTI) group, 8000 U/mL ulinastatin; (4) IL-1<i>α</i> (10 ng/mL) + plasminogen group (10 <i>μ</i>g/mL); (5) IL-1<i>α</i> (10 ng/mL) + plasminogen (10 <i>μ</i>g/mL) + L-UTI group (800 U/mL); (6) IL-1<i>α</i> (10 ng/mL) + plasminogen (10 <i>μ</i>g/mL) + L-UTI group (8000 U/mL); (7) GM6001 group (0.8 nmol/L).</table>

BioMed Research International

fig2

Figure 2

Figure 2: Ulinastatin Reduces Cancer Recurrence after Resection of Hepatic Metastases from Colon Cancer by Inhibiting MMP-9 Activation via the Antifibrinolytic Pathway 

Figure 2 | Ulinastatin Reduces Cancer Recurrence after Resection of Hepatic Metastases from Colon Cancer by Inhibiting MMP-9 Activation via the Antifibrinolytic Pathway 